Peter the Bridge, Saint Petersburg, Russia

The NEOMED Institute Is Attending the 25th BIO International Convention ​in Boston

May 31st, 2018 |Announcement| No Comments

NEOMED’s objectives for BIO:

• Identify licensing partners/financial partners for NEOMED’s therapeutic pipeline
• Identify new in-licensing opportunities
• Showcase NEOMED Innovation Center’s expansion project

 

Montreal, QC, Canada May 31st, 2018 – The NEOMED Institute announced its participation at the 25th BIO International Convention, from June 4th to the 7th, in Boston.

“BIO continues to be a tremendous partnering event for NEOMED. It provides for the opportunity to carry on existing conversations and start new ones with potential partners interested in our rich portfolio of assets that we are looking to license. I look forward to the many 1-on-1 meetings we have scheduled” rejoiced Daniel Böck, NEOMED Institute’s Vice President of Business Development.

“NEOMED is actively seeking promising drug discovery projects based on innovative therapeutic targets. With more than 16,000 attendees, BIO 2018 is an important event to explore new potential in-licensing opportunities coming from academia” added Patricia Escoffier, NEOMED Institute’s Scientific Affairs Director.

During the Convention, Donald Olds, NEOMED Institute’s President and CEO, will also be a panelist at the National Panel on Accelerators and Incubators, organized by BIOTECanada on Tuesday June 5th. “I am very excited to have been invited by BIOTECanada to participate in their national panel on accelerators and incubators.  We are very proud of the success we have had over our first 5 years creating a leading Canadian life sciences ecosystem with over 30 companies and 350 employees and continuing our work to advance great Canadian science from our universities and research centers towards successful commercialization” declared Donald Olds.

BIO is also an anticipated event for the “NEOMED Innovation Center, division of the NEOMED Institute, which is currently seeking new tenants to be part of the 50,000 ft2expansion of Labs and offices and join the already established ecosystem of 20 companies and 300 scientists, at our Montreal’s site” concluded Pierre-Yves Desbiens, Chief Operating Officer of the Institute.

 

About the NEOMED Institute (NEOMED)
The NEOMED Institute is a successful and innovative Canadian not-for-profit R&D organization with a single mission: to enable and accelerate the commercialization of Canadian life science discoveries. To accomplish this mission, NEOMED Institute operates two complementary and integrated divisions:

  • NEOMED Therapeutics in-licenses great scientific discoveries from Canadian academic centers and research institutes and then funds and develops these programs to stages that are attractive for partnering or stand-alone financing. All proceeds from successful out-licensing and exits are re-invested in new pipeline projects.
  • NEOMED Innovation Center operates a world-class life sciences ecosystem in Montreal, Quebec, that was created as an enabling environment for biotechnology and contract research organizations to establish, grow and prosper. Today the NEOMED Innovation Centre hosts 30 life sciences companies employing over 350 people who work in our two state-of-the-art R&D centres. Our tenants benefit from NEOMED’s shared services model (analytical chemistry/in vivo pharmacology, etc.) and an entrepreneurial culture enabled by collaboration and scientific innovation.

The NEOMED Institute is funded by pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada as well as the revenue generated from the out-licensing/sale of their pipeline projects and the operation of their facilities. For more information, please visit www.neomed.ca.

 

NEOMED Media Enquiries:
Shirley Robinet
Communications Coordinator
NEOMED Institute
Tel.: 514-367-1212 ext. 218
srobinet@neomed.ca

Share this

Similar News

image articles
14 November 2018

NEOMED Institute Announces the Appointment of Dr. Youssef Bennani to its Board of Directors

Read complete news
image articles
4 September 2018

Ampersand Invests in Management Buyout of Clinical Immunology Provider NEOMED-LABS from the NEOMED Institute

Read complete news
© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia